NGS-based Large-panel in Targeted Drug Delivery and Immunotherapy of Lung Cancer

A Prospective Study on Companion Diagnosis by NGS-based Large-panel in Targeted Drug Delivery and Immunotherapy of Lung Cancer

Companion diagnosis by large-panel is in increasing acceptance and need during clinical cancer management. The purpose of this trial is to investigate the benefit of large-panel NGS analysis in companion diagnosis of advanced lung cancer patients and further optimize the parameters.

Fresh tumor tissues and matched blood cells will be analyzed by large-panel (Berryoncology, lnc.) for multiple molecular biomarkers including mutations with sensitivity/resistance to targeted therapies, tumor mutational burden (TMB), microsatellite instability (MSI) status, etc., Therapeutic approach and outcome will be followed-up to inspect the clinical benefit by large-panel analysis. In addition, selected samples will be analyzed by WES to assess the correctness of TMB estimated by large-panel.

Inclusion Criteria:

• Participant aged 18 or above, and gender unrestricted
• Individual with pathologically diagnosed lung cancer

Exclusion Criteria:

• Patients with concomitant other tumors
• Individual with severe cardiopulmonary insufficiency and hypoproteinemia
• Women who were pregnant and were during their lactation